首页> 美国卫生研究院文献>Clinical Ophthalmology (Auckland N.Z.) >Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma

【2h】

Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma

机译：Ripasudil Endgame：Rho-激酶抑制剂作为最后耐受性医学治疗的最后漏斗的作用以患者高级青光眼

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

To elucidate the use of Ripasudil in patients of advanced glaucoma on maximally tolerated medical therapy who could not be offered the option of surgery due to the global pandemic lockdown.

机译：为了阐明利用Ripasudil对高耐受性医疗疗法的肝硬化，由于全球大流行锁定而无法提供手术的选择。

著录项

期刊名称 Clinical Ophthalmology (Auckland N.Z.)
作者
Mayuresh Naik; Monika Kapur; VishnuSwarup Gupta; HarinderSingh Sethi; Kartikeya Srivastava;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类眼科学;
关键词

机译：高级青光眼;RIPAUSDIL;ROCK1抑制剂;最大耐受药物治疗;Covid-19锁定;
入库时间 2022-08-21 12:18:28

相似文献

外文文献
中文文献
专利

1. Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy [J] . Sato Shino, Hirooka Kazuyuki, Nitta Eri, Advances in therapy. . 2016,第9期

机译：在其他最大耐受的药物治疗后无法获得足够控制的青光眼患者中，Rho激酶抑制剂利帕舒地尔的眼内压降低作用
2. Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy [J] . Inazaki Hiroshi, Kobayashi Satoshi, Anzai Yoko, Journal of glaucoma . 2017,第2期

机译：Ripasudil（Rho-激酶抑制剂）额外用途的疗效在最大的医疗治疗下患有青光眼患者的患者
3. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy [J] . Inazaki Hiroshi, Kobayashi Satoshi, Anzai Yoko, Graefe's archive for clinical and experimental ophthalmology: Albrecht von Graefes Archiv fur klinische und experimentelle Opthalmologie . 2017,第10期

机译：升性的辅助使用RIPASUDIL，RHO-激酶抑制剂，青光眼患者的疗效效果，最大的医疗治疗
4. Effect of Telmisartan Therapy On Blood Pressure and Metabolic Parameters Control If ACE Inhibitors Are Not Tolerated. SONAR Survey. [C] . Filipova S. International Conference on Pre-hypertension Cardio Metabolic Syndrome . 2011

机译：Telmisartan治疗对血压和代谢参数控制的影响如果不耐受ACE抑制剂。声纳调查。
5. New approaches for treatment of erectile dysfunction in conditions of low nitric oxide formation or bioavailability: Investigation of rho-kinase inhibitors and soluble guanylate cyclase-targeted therapies. [D] . Lasker, George Franklin. 2016

机译：在低一氧化氮形成或生物利用度条件下治疗勃起功能障碍的新方法：研究rho激酶抑制剂和可溶性鸟苷酸环化酶靶向疗法。
6. Effect of latanoprost on intraocular pressure in patients with glaucoma on maximal tolerated medical treatment [O] . A. AZUARA-BLANCO, L KATZ, G. SPAETH, 1997

机译：拉坦前列素对青光眼患者最大眼压治疗的眼压的影响
7. Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma [O] . Mayuresh Naik, Monika Kapur, VishnuSwarup Gupta, 2021

机译：Ripasudil Endgame：Rho-激酶抑制剂作为最后耐受性医学治疗的最后漏斗的作用，以患者高级青光眼

Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma

摘要

著录项

相似文献

相关主题

期刊订阅